245 related articles for article (PubMed ID: 36310384)
1. DDX24 regulates the chemosensitivity of hepatocellular carcinoma to sorafenib via mediating the expression of SNORA18.
Gan H; Li L; Hu X; Cai J; Hu X; Zhang H; Zhao N; Xu X; Guo H; Pang P
Cancer Biol Ther; 2022 Dec; 23(1):1-14. PubMed ID: 36310384
[TBL] [Abstract][Full Text] [Related]
2. DEAD-Box Helicase 17 circRNA (circDDX17) Reduces Sorafenib Resistance and Tumorigenesis in Hepatocellular Carcinoma.
Zhang X; Wang W; Mo S; Sun X
Dig Dis Sci; 2024 Jun; 69(6):2096-2108. PubMed ID: 38653946
[TBL] [Abstract][Full Text] [Related]
3. Microbiota-derived SSL6 enhances the sensitivity of hepatocellular carcinoma to sorafenib by down-regulating glycolysis.
Zhang X; Wu L; Xu Y; Yu H; Chen Y; Zhao H; Lei J; Zhou Y; Zhang J; Wang J; Peng J; Jiang L; Sheng H; Li Y
Cancer Lett; 2020 Jul; 481():32-44. PubMed ID: 32246956
[TBL] [Abstract][Full Text] [Related]
4. l-Methionine potentiates anticancer activity of Sorafenib by epigenetically altering DUSP3/ERK pathway in hepatocellular carcinoma.
Pal S; Kabeer SW; Sharma S; Tikoo K
J Biochem Mol Toxicol; 2024 Mar; 38(3):e23663. PubMed ID: 38367245
[TBL] [Abstract][Full Text] [Related]
5. lncRNA-POIR promotes epithelial-mesenchymal transition and suppresses sorafenib sensitivity simultaneously in hepatocellular carcinoma by sponging miR-182-5p.
Chen BW; Zhou Y; Wei T; Wen L; Zhang YB; Shen SC; Zhang J; Ma T; Chen W; Ni L; Wang Y; Bai XL; Liang TB
J Cell Biochem; 2021 Jan; 122(1):130-142. PubMed ID: 32951268
[TBL] [Abstract][Full Text] [Related]
6. Ginsenoside Rg3 and sorafenib combination therapy relieves the hepatocellular carcinomaprogression through regulating the HK2-mediated glycolysis and PI3K/Akt signaling pathway.
Wei Q; Ren Y; Zheng X; Yang S; Lu T; Ji H; Hua H; Shan K
Bioengineered; 2022 May; 13(5):13919-13928. PubMed ID: 35719058
[TBL] [Abstract][Full Text] [Related]
7. RAD51 Inhibition Shows Antitumor Activity in Hepatocellular Carcinoma.
Pan M; Sha Y; Qiu J; Chen Y; Liu L; Luo M; Huang A; Xia J
Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175611
[TBL] [Abstract][Full Text] [Related]
8. Long Noncoding RNA MALAT1 Contributes to Sorafenib Resistance by Targeting miR-140-5p/Aurora-A Signaling in Hepatocellular Carcinoma.
Fan L; Huang X; Chen J; Zhang K; Gu YH; Sun J; Cui SY
Mol Cancer Ther; 2020 May; 19(5):1197-1209. PubMed ID: 32220970
[TBL] [Abstract][Full Text] [Related]
9. LncRNA LIMT (LINC01089) contributes to sorafenib chemoresistance via regulation of miR-665 and epithelial to mesenchymal transition in hepatocellular carcinoma cells.
Sun J; Zheng X; Wang B; Cai Y; Zheng L; Hu L; Lu X; Xie S; Zhang X; Liu H; Ye L
Acta Biochim Biophys Sin (Shanghai); 2022 Jan; 54(2):261-270. PubMed ID: 35130616
[TBL] [Abstract][Full Text] [Related]
10. SNGH16 regulates cell autophagy to promote Sorafenib Resistance through suppressing miR-23b-3p via sponging EGR1 in hepatocellular carcinoma.
Jing Z; Ye X; Ma X; Hu X; Yang W; Shi J; Chen G; Gong L
Cancer Med; 2020 Jun; 9(12):4324-4338. PubMed ID: 32324343
[TBL] [Abstract][Full Text] [Related]
11. RNA Helicase DDX24 Stabilizes LAMB1 to Promote Hepatocellular Carcinoma Progression.
Liu T; Gan H; He S; Deng J; Hu X; Li L; Cai L; He J; Long H; Cai J; Li H; Zhang Q; Wang L; Chen F; Chen Y; Zhang H; Li J; Yang L; Liu Y; Yang JH; Kuang DM; Pang P; He H; Shan H
Cancer Res; 2022 Sep; 82(17):3074-3087. PubMed ID: 35763670
[TBL] [Abstract][Full Text] [Related]
12. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
[TBL] [Abstract][Full Text] [Related]
13. Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib.
Zheng N; Liu W; Li B; Nie H; Liu J; Cheng Y; Wang J; Dong H; Jia L
J Exp Clin Cancer Res; 2019 May; 38(1):232. PubMed ID: 31151472
[TBL] [Abstract][Full Text] [Related]
14. Upregulation of SNX5 predicts poor prognosis and promotes hepatocellular carcinoma progression by modulating the EGFR-ERK1/2 signaling pathway.
Zhou Q; Huang T; Jiang Z; Ge C; Chen X; Zhang L; Zhao F; Zhu M; Chen T; Cui Y; Li H; Yao M; Li J; Tian H
Oncogene; 2020 Mar; 39(10):2140-2155. PubMed ID: 31819169
[TBL] [Abstract][Full Text] [Related]
15. Y-box binding protein 1 augments sorafenib resistance
Liu T; Xie XL; Zhou X; Chen SX; Wang YJ; Shi LP; Chen SJ; Wang YJ; Wang SL; Zhang JN; Dou SY; Jiang XY; Cui RL; Jiang HQ
World J Gastroenterol; 2021 Jul; 27(28):4667-4686. PubMed ID: 34366628
[TBL] [Abstract][Full Text] [Related]
16. Treatment with a New Barbituric Acid Derivative Exerts Antiproliferative and Antimigratory Effects against Sorafenib Resistance in Hepatocellular Carcinoma.
Liao YJ; Hsu SM; Chien CY; Wang YH; Hsu MH; Suk FM
Molecules; 2020 Jun; 25(12):. PubMed ID: 32575795
[TBL] [Abstract][Full Text] [Related]
17. XPO1 intensifies sorafenib resistance by stabilizing acetylation of NPM1 and enhancing epithelial-mesenchymal transition in hepatocellular carcinoma.
Wang Z; Pan B; Yao Y; Qiu J; Zhang X; Wu X; Tang N
Biomed Pharmacother; 2023 Apr; 160():114402. PubMed ID: 36791564
[TBL] [Abstract][Full Text] [Related]
18. Targeted Therapy for Hepatocellular Carcinoma: Co-Delivery of Sorafenib and Curcumin Using Lactosylated pH-Responsive Nanoparticles.
Bian Y; Guo D
Drug Des Devel Ther; 2020; 14():647-659. PubMed ID: 32109990
[TBL] [Abstract][Full Text] [Related]
19. IGF-1R down regulates the sensitivity of hepatocellular carcinoma to sorafenib through the PI3K / akt and RAS / raf / ERK signaling pathways.
Cai W; Ma Y; Song L; Cao N; Gao J; Zhou S; Tang X
BMC Cancer; 2023 Jan; 23(1):87. PubMed ID: 36698167
[TBL] [Abstract][Full Text] [Related]
20. Wild type Kirsten rat sarcoma is a novel microRNA-622-regulated therapeutic target for hepatocellular carcinoma and contributes to sorafenib resistance.
Dietrich P; Koch A; Fritz V; Hartmann A; Bosserhoff AK; Hellerbrand C
Gut; 2018 Jul; 67(7):1328-1341. PubMed ID: 29275358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]